Compare Stocks

→ Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BGXX Bright Green	$0.19 +2.1%	$0.24	$0.15 ▼ $1.81	$35.71M	0.72	1.67 million shs	123,280 shs
CDXC ChromaDex	$3.48 +2.7%	$2.85	$1.25 ▼ $4.65	$262.08M	1.99	261,413 shs	135,701 shs
MNMD Mind Medicine (MindMed)	$8.58 +0.7%	$8.39	$2.41 ▼ $12.22	$602.92M	2.81	1.89 million shs	485,491 shs

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BGXX Bright Green	-6.12%	-17.34%	-24.09%	-20.00%	-85.85%
CDXC ChromaDex	-0.29%	-10.55%	-11.72%	+121.57%	+156.82%
MNMD Mind Medicine (MindMed)	+0.71%	-4.38%	-13.59%	+130.89%	+134.71%

Move Your Money Before May 1 (Ad)

Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens?

Click here to get the full story before May 1.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BGXX Bright Green	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CDXC ChromaDex	3.5007 of 5 stars	3.5	2.0	0.0	4.1	1.1	0.8	0.6
MNMD Mind Medicine (MindMed)	2.1598 of 5 stars	3.5	3.0	0.0	0.0	2.5	0.8	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BGXX Bright Green	N/A	N/A	N/A	N/A
CDXC ChromaDex	3.00	Buy	$5.87	68.58% Upside
MNMD Mind Medicine (MindMed)	3.00	Buy	$25.20	193.71% Upside

Current Analyst Ratings

Latest CDXC, BGXX, and MNMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/15/2024	MNMD Mind Medicine (MindMed)	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
4/15/2024	MNMD Mind Medicine (MindMed)	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$20.00
4/9/2024	CDXC ChromaDex	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.25 ➝ $6.00
3/14/2024	MNMD Mind Medicine (MindMed)	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00
3/1/2024	MNMD Mind Medicine (MindMed)	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00
2/29/2024	MNMD Mind Medicine (MindMed)	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$14.00 ➝ $15.00

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BGXX Bright Green	N/A	N/A	N/A	N/A	$0.06 per share	N/A
CDXC ChromaDex	$83.57M	3.14	N/A	N/A	$0.38 per share	9.16
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	$1.90 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BGXX Bright Green	-$13.13M	-$0.08	N/A	∞	N/A	N/A	-101.64%	-57.83%	5/27/2024 (Estimated)
CDXC ChromaDex	-$4.94M	-$0.07	N/A	58.00	N/A	-5.91%	-17.81%	-9.17%	5/8/2024 (Confirmed)
MNMD Mind Medicine (MindMed)	-$95.73M	-$2.45	N/A	N/A	N/A	N/A	-89.72%	-65.33%	5/2/2024 (Estimated)

Latest CDXC, BGXX, and MNMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2024	N/A	CDXC ChromaDex	-$0.03	N/A	+$0.03	N/A	N/A	N/A
2/28/2024	Q4 2023	MNMD Mind Medicine (MindMed)	-$0.48	-$0.59	-$0.11	-$0.59	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BGXX Bright Green	N/A	N/A	N/A	N/A	N/A
CDXC ChromaDex	N/A	N/A	N/A	N/A	N/A
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BGXX Bright Green	0.02	0.04	0.04
CDXC ChromaDex	N/A	2.40	1.70
MNMD Mind Medicine (MindMed)	0.18	3.22	3.22

Ownership

Institutional Ownership

Company	Institutional Ownership
BGXX Bright Green	7.83%
CDXC ChromaDex	15.41%
MNMD Mind Medicine (MindMed)	27.91%

Insider Ownership

Company	Insider Ownership
BGXX Bright Green	51.38%
CDXC ChromaDex	10.57%
MNMD Mind Medicine (MindMed)	2.11%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
BGXX Bright Green	23	190.17 million	92.46 million	Optionable
CDXC ChromaDex	106	75.31 million	67.35 million	Optionable
MNMD Mind Medicine (MindMed)	57	70.27 million	68.79 million	Optionable

CDXC, BGXX, and MNMD Headlines

Source	Headline
	MindMed: Breakthrough Status From The FDA For LSD Therapy seekingalpha.com - April 26 at 11:13 AM
	The Top 3 Small-Cap Stocks to Buy in April 2024 investorplace.com - April 25 at 3:00 PM
	MindMed to Present at Upcoming May Medical Conferences businesswire.com - April 25 at 7:00 AM
	This Small-Cap Stock Is Up 140% This Year and Here's Why It Can Go Even Higher fool.com - April 25 at 5:37 AM
	Mind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Up 6.8% marketbeat.com - April 23 at 3:43 PM
	Mind Medicine (MindMed) (NASDAQ:MNMD) Trading Down 3.5% marketbeat.com - April 22 at 2:53 PM
	Jim Cramer Slams Political Blocking Of 'LSD-Derived Antidepressants,' Citing Strong Test Data 'Showing They Worked' msn.com - April 19 at 7:58 PM
	Mind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Down 2.9% marketbeat.com - April 18 at 3:41 PM
	Leerink Partnrs Reaffirms Outperform Rating for Mind Medicine (MindMed) (NASDAQ:MNMD) americanbankingnews.com - April 18 at 2:02 AM
	Analysts Set Expectations for Mind Medicine (MindMed) Inc.'s Q1 2024 Earnings (NASDAQ:MNMD) americanbankingnews.com - April 18 at 1:28 AM
	Leerink Partnrs Weighs in on Mind Medicine (MindMed) Inc.'s Q1 2024 Earnings (NASDAQ:MNMD) marketbeat.com - April 17 at 4:48 PM
	Leerink Partnrs Reaffirms "Outperform" Rating for Mind Medicine (MindMed) (NASDAQ:MNMD) marketbeat.com - April 17 at 4:40 PM
	Mind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Down 3.1% marketbeat.com - April 17 at 1:11 PM
	Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Gap Up to $9.67 americanbankingnews.com - April 17 at 5:15 AM
	Leerink Partners Initiates Coverage of Mind Medicine (MNMD) with Outperform Recommendation msn.com - April 16 at 10:36 AM
	Mind Medicine (MindMed) (NASDAQ:MNMD) Coverage Initiated by Analysts at SVB Leerink americanbankingnews.com - April 16 at 4:50 AM
	Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Short Interest Up 23.2% in March marketbeat.com - April 15 at 9:35 PM
	SVB Leerink Initiates Coverage on Mind Medicine (MindMed) (NASDAQ:MNMD) marketbeat.com - April 15 at 8:35 AM
	Mind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Down 6.5% marketbeat.com - April 11 at 2:49 PM
	Mind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Up 7.3% marketbeat.com - April 10 at 1:39 PM
	Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Given Average Recommendation of "Buy" by Analysts marketbeat.com - April 10 at 2:14 AM
	Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Down 5.4% marketbeat.com - April 9 at 12:54 PM
	Mind Medicine (MindMed) (NASDAQ:MNMD) Trading 3.2% Higher marketbeat.com - April 8 at 12:46 PM
	MindMed (MNMD) Stock Rises 154% in 3 Months: Here's Why zacks.com - April 8 at 8:01 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Bright Green

NASDAQ:BGXX

Bright Green Corporation focuses on the cultivation, manufacture, and sale of cannabis and cannabis-related products. Its products are used in research, pharmaceutical applications, and affiliated exports. The company was incorporated in 2019 and is based in Grants, New Mexico.

ChromaDex

NASDAQ:CDXC

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

Mind Medicine (MindMed)

NASDAQ:MNMD

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial